Phillips Wealth Planners LLC Has $341,000 Stock Holdings in AstraZeneca PLC (NASDAQ:AZN)

Phillips Wealth Planners LLC cut its holdings in shares of AstraZeneca PLC (NASDAQ:AZN) by 29.3% during the 4th quarter, Holdings Channel reports. The institutional investor owned 5,091 shares of the company’s stock after selling 2,109 shares during the quarter. Phillips Wealth Planners LLC’s holdings in AstraZeneca were worth $341,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. McClarren Financial Advisors Inc. boosted its position in AstraZeneca by 320.8% during the 3rd quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock worth $25,000 after buying an additional 247 shares during the period. Capital Performance Advisors LLP acquired a new stake in AstraZeneca during the 3rd quarter worth approximately $28,000. Albion Financial Group UT boosted its position in AstraZeneca by 68.9% during the 4th quarter. Albion Financial Group UT now owns 608 shares of the company’s stock worth $40,000 after buying an additional 248 shares during the period. Groupama Asset Managment boosted its position in AstraZeneca by 22.9% during the 3rd quarter. Groupama Asset Managment now owns 543,398 shares of the company’s stock worth $42,000 after buying an additional 101,225 shares during the period. Finally, Ashton Thomas Securities LLC acquired a new position in shares of AstraZeneca in the 3rd quarter worth approximately $45,000. 20.35% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the stock. UBS Group upgraded shares of AstraZeneca from a “sell” rating to a “neutral” rating in a research report on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $89.75.

AstraZeneca Stock Performance

NASDAQ:AZN opened at $68.20 on Thursday. The company has a fifty day moving average of $66.20 and a 200-day moving average of $74.32. The firm has a market capitalization of $211.49 billion, a P/E ratio of 32.63, a P/E/G ratio of 1.13 and a beta of 0.46. The company has a quick ratio of 0.71, a current ratio of 0.93 and a debt-to-equity ratio of 0.71. AstraZeneca PLC has a twelve month low of $60.47 and a twelve month high of $87.68.

AstraZeneca (NASDAQ:AZN) last released its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 earnings per share for the quarter, beating the consensus estimate of $1.01 by $0.03. The company had revenue of $13.57 billion during the quarter, compared to analyst estimates of $13.08 billion. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. AstraZeneca’s revenue for the quarter was up 18.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.87 EPS. As a group, sell-side analysts anticipate that AstraZeneca PLC will post 4.12 EPS for the current year.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.